Type 2 diabetes and psoriasis: links and risks

Jesper Grønlund Holm, Simon Francis Thomsen, Jesper Grønlund Holm, Simon Francis Thomsen

Abstract

Psoriasis (PsO) is one of the most common chronic inflammatory skin diseases with a world prevalence of 2%-4%. The increasing knowledge of the mechanisms driving PsO has raised focus on existing links to metabolic syndrome and type 2 diabetes (T2D). We reviewed the existing literature of the prevalence and risk of T2D in patients with PsO. The studies reviewed were mainly large retrospective cohort and case-control studies, showing an increased prevalence of T2D in PsO patients compared to controls, particularly in late onset (type 2) PsO. T2D prevalence did not correlate to patient age or severity of PsO in the reviewed studies. Conclusively, T2D was found to be more prevalent in patients with PsO compared to the background population. Several mechanisms involved in lipid transportation seem to be upregulated in PsO patients. Physicians play a key role concerning information about known comorbidity and promotion of early prophylaxis in patients with PsO.

Keywords: association; link; psoriasis; risk; type 2 diabetes.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
    1. Oliveira M de F, Rocha B de O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.
    1. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus. JAMA Dermatol. 2013;149(1):84–91.
    1. Coto-Segura P, Eiris-Salvado N, González-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169(4):783–793.
    1. Baeta IG, Bittencourt FV, Gontijo B, Goulart EM. Comorbidities and cardiovascular risk factors in patients with psoriasis. An Bras Dermatol. 2014;89(5):735–744.
    1. Gisondi P, Cazzaniga S, Chimenti S, et al. Psocare Study Group Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare registry. J Eur Acad Dermatology Venereol. 2013;27(1):e30–e41.
    1. Phan C, Sigal ML, Lhafa M, et al. GEM Resopso. Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases. Ann Dermatol Venereol. 2016;143(4):264–274.
    1. Phan C, Sigal ML, Estève E, et al. GEM RESOPSO Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78–82.
    1. Sanchez-Carazo JL, López-Estebaranz JL, Guisado C. Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study) J Dermatol. 2014;41(8):673–678.
    1. Vanaclocha F, Crespo-Erchiga V, Jiménez-Puya R, et al. Investigadores del estudio AQUILES Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study. Actas Dermosifiliogr. 2015;106(1):35–43. English, Spanish.
    1. Pongpit J, Porntharukchareon S, Kaewduang P, et al. Liver stiffness measurement in psoriasis: do metabolic or disease factors play the important role? BioMed Research International. 2016;2016(5):1–6.
    1. Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart. 2017;103(23):1867–1873.
    1. Kojanova M, Fialova J, Cetkovska P, et al. BIOREP study group Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428–434.
    1. Xu X, Su L, Gao Y, Ding Y. The prevalence of nonalcoholic fatty liver disease and related metabolic comorbidities was associated with age at onset of moderate to severe plaque psoriasis: a cross-sectional study. PLoS One. 2017;12(1):e0169952.
    1. Adışen E, Uzun S, Erduran F, Gürer MA. Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. An Bras Dermatol. 2018;93(2):205–211.
    1. Mihai VV, Iulia S, Alexandra P, et al. Gene polymorphisms of TNF-238G / a, TNF-308G / a, IL10-1082G / a, TNFAIP3, and MC4R and comorbidity occurrence in a Romanian population with psoriasis. J Med Life. 2018;11(1):69–74.
    1. Kwa MC, Silverberg JI. Association between inflammatory skin disease and cardiovascular and cerebrovascular comorbidities in US adults: analysis of nationwide inpatient sample data. Am J Clin Dermatol. 2017;18(6):813–823.
    1. Kimball AB, Leonardi C, Stahle M, et al. PSOLAR Steering Committee Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR) Br J Dermatol. 2014;171(1):137–147.
    1. Ucak S, Ekmekci T, Basat O, Koslu A, Altuntas Y. Comparison of various insulin sensivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venerol. 2006;20(5):517–522.
    1. Armstrong AW, Guérin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015;72(6):968–977.e2.
    1. Lee A, Smith SD, Hong E, Garnett S, Fischer G. Association between pediatric psoriasis and Waist-to-Height ratio in the absence of obesity: a multicenter Australian study. JAMA Dermatol. 2016;152(12):1314–1319.
    1. Jacob L, Kostev K. Psoriasis risk in patients with type 2 diabetes in German primary care practices. Prim Care Diabetes. 2017;11(1):52–56.
    1. Parisi R, Rutter MK, Lunt M, et al. Identification and Management of Psoriasis Associated ComorbidiTy (IMPACT) project team Psoriasis and the risk of major cardiovascular events: cohort study using the clinical Practice Research Datalink. J Invest Dermatol. 2015;135(9):2189–2197.
    1. Bang CN, Okin PM, Køber L, Wachtell K, Gottlieb AB, Devereux RB. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the losartan intervention for endpoint study. J Hypertens. 2014;32(3):667–672.
    1. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328.
    1. Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol. 2014;70(4):691–698.
    1. Polic M, Miskulin M, Smolic M, et al. Psoriasis severity—a risk factor of insulin resistance independent of metabolic syndrome. Int J Environ Res Public Health. 2018;15(7):E1486.
    1. Naldi L, Chatenoud L, Belloni A, et al. Medical history, drug exposure and the risk of psoriasis. Evidence from an Italian case-control study. Dermatology. 2008;216(2):125–130. discussion 130–132.
    1. Mahé E, Maccari F, Beauchet A, et al. Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. Br J Dermatol. 2013;169(4):889–895.
    1. Karoli R, Fatima J, Shukla V, et al. A study of cardio - metabolic risk profile in patients with psoriasis. J Assoc Physicians India. 2013;61(11):798–803.
    1. Ritchlin CT, Colbert RA, Gladman DD, Arthritis P. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970.
    1. Dubreuil M, Rho YH, A M, Man A. Original article diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 2014;53(2):346–352.
    1. Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis. 2010;69(12):2114–2117.
    1. Edson-Heredia E, Zhu B, Lefevre C, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2015;29(5):955–963.
    1. Nas K, Karkucak M, Durmus B, et al. Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. Int J Rheum Dis. 2015;18(8):873–879.
    1. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011;63(12):1729–1735.
    1. Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315–322.e1.
    1. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1–776.
    1. Bostoen J, Van Praet L, Brochez L, Mielants H, Lambert J. A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. J Eur Acad Dermatol Venereol. 2014;28(4):507–511.
    1. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982–986.
    1. Christophers EHT. Patient subgroups and the inflammatory pattern in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989;151:88–92. discussion 106–110.
    1. Theodorakopoulou E, Yiu ZZ, Bundy C, et al. Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. Br J Dermatol. 2016;175(5):1038–1044.
    1. Radtke MA, Schäfer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31(1):151–157.
    1. Cho JS, Pietras EM, Garcia NC. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice Find the latest version: IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. 2010;120(5):1762–1773.
    1. Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015;136(1):104–115.e7.
    1. Cheung L, Fisher RM, Kuzmina N, et al. Psoriasis skin inflammation-induced microRNA-26b targets NCEH1 in underlying subcutaneous adipose tissue. J Invest Dermatol. 2016;136(3):640–648.
    1. Buquicchio R, Foti C, Loconsole F, Polimeno L, Ventura MT. Clusterin serum level: how does it affect psoriatic patients? J Biol Regul Homeost Agents. 2017;31(3):785–789.
    1. García-Rodríguez S, Arias-Santiago S, Perandrés-López R, et al. Decreased plasma levels of clusterin in patients with psoriasis. Actas Dermo-Sifiliográficas. 2013;104(6):497–503.
    1. Zhang C, Zhu KJ, Liu H, et al. The TNFAIP3 polymorphism rs610604 both associates with the risk of psoriasis vulgaris and affects the clinical severity. Clin Exp Dermatol. 2015;40(4):426–430.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅